Novartis
Novartis is a global healthcare company that provides solutions to address the evolving needs of patients worldwide. The Company's businesses are divided into three operating divisions: Pharmaceuticals, Alcon (eye care) and Sandoz (generics). Novartis manufactures the drugs clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan) and imatinib mesylate (Gleevec/Glivec). Additional agents include ciclosporin (Neoral/Sandimmun), letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil) and others. The Company is one of the largest pharmaceutical companies by both market cap and sales.
Company Growth (employees)
Novartis was founded in 1996 and is headquartered in Basel, CH
Key People at Novartis
Joseph Jimenez
Chief Executive Officer
Harry Kirsch
Chief Financial Officer
Paul van Arkel
Head of Corporate Strategy and Healthcare Systems
Peter Elam
Head of Internal Audit
Erwin Vanhaecke
Head Novartis Group Quality
Michael Willi
Group Head of Communications
Felix Ehrat
Group General Counsel
Richard Francis
CEO, Sandoz
Andre Wyss
President, Novartis Operations Country President for Switzerland
Juergen Brokatzky-Geiger
Global Head, Corporate Responsibility for Novartis
Michael Ball
CEO, Alcon
James Bradner
President, Novartis Institutes for BioMedical Research
Paul Hudson
CEO, Novartis Pharmaceuticals
Bruno Strigini
CEO, Novartis Oncology
Steven Baert
Head of Human Resources
Novartis Office Locations
Novartis has offices in Basel, East Hanover, New York, Wehr and in 2 other locations
Basel, CH (HQ)
Forum 1, Novartis Campus
Tokyo, JP
Toranomon Hills, Mori Tower, 1-23-1, Toranomon, Minato-ku
Beijing, CN
14th floor, China World Tower 2, No.1 Jian Guo Men Wai Avenue, Chao Yang District
Wehr, DE
Oeflingerstrasse 44
New York, US
230 Park Avenue, 21st Floor
East Hanover, US
1 Health Plazam, Bldg. 101
Novartis Data and Metrics
Novartis Financial Metrics
Novartis's revenue was reported to be $48.5 b in FY, 2016 which is a 2% decrease from the previous period.
USD
Revenue (FY, 2016) | 48.5 b |
Revenue growth (FY, 2015 - FY, 2016), % | (2%) |
Gross profit (FY, 2016) | 31 b |
Gross profit margin (FY, 2016), % | 64% |
Net income (FY, 2016) | 6.7 b |
Market capitalization (31-Jan-2017) | 175.5 b |
Closing share price (31-Jan-2017) | 72.3 |
Novartis's current market capitalization is $175.5 b.
- Source: Company Filings
| USD | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|
Revenue | 53.6 b | 49.4 b | 48.5 b |
Revenue growth, % | (8%) | (2%) | |
Cost of goods sold | 17.3 b | 17.4 b | 17.5 b |
Gross profit | 36.3 b | 32 b | 31 b |
- Source: Company Filings
| USD | FY, 2015 | FY, 2016 |
|---|---|---|
Cash From Operating Activities | 12.1 b | 11.5 b |
| USD | Y, 2016 |
|---|---|
Revenue/Employee | 411.2 k |
Novartis Operating Metrics
| Y, 2015 | Y, 2016 | |
|---|---|---|
Patients Reached | 972 m | 965 m |
Projects Entering Development Pipeline | 8 | 5 |
Major Submissions (US, EU, JP) | 14 | 24 |
Major Approvals (US, EU, JP) | 20 | 16 |
Novartis Market Value History
Novartis Revenue Breakdown
Novartis Job Categories
Novartis Median Salaries
Source: 453 public H-1B filings from Novartis
Market Position of Novartis
Traffic Overview of Novartis
Novartis Online and Social Media Presence
Novartis News and Updates
January 25, 2017
Watch out: Novartis mulls spin-off of eyecare business
Novartis may spin off its struggling Alcon eye care business as it looks at ways to boost growth The Swiss drugmaker also plans to buy back up to $5bn (£4bn) of shares over the next year in a bid to return to growth by 2018. Alcon has slumped to a $120m loss as fourth-quarter sales dipped. Nov…
December 21, 2016
Novartis CEO: Here’s How To Make Healthcare More Accessible Now
Our future is at stake.
November 20, 2016
Novartis backs off from 2016 date for testing Google’s smart contact lens
Novartis has abandoned a 2016 goal to start testing its autofocus contact lens on people, though it said the groundbreaking product it is making with internet giant Google is "progressing steadily."
November 02, 2016
Big Tech And Pharma Bet On Cancer Therapy Startups: Celgene, Novartis, Pfizer, and Google’s Investments
Corporate interest in life-science startups developing cancer therapies has been increasing over the years. Corporate-backed deals are up from around 30 in 2012 to nearly 50 so far this year (as of 10/26/16). Apart from big pharma companies like Novartis, … Continued
September 17, 2016
Novartis Says MS Drug Cut Risk of Disability Advance in Study
"These data are a positive stride forward," says Novartis CMO.